Rationalization of drug therapy by the hospital pharmacistKRÄMER, I.International journal of clinical pharmacology and therapeutics. 1995, Vol 33, Num 8, pp 473-474, issn 0946-1965Article

Good Manufacturing Practice in der aseptischen Herstellung applikationsfertiger Parenteralia in der Apotheke : Ein Vorschlag für eine spezifische, nationale Richtlinie = Good manufacturing practice for the aseptic preparation of ready-to-use parenteral administration forms in pharmacies : Proposal for a specific national guidelineKRÄMER, I.Pharmazeutische Industrie. 1998, Vol 60, Num 9, pp 787-794, issn 0031-711XArticle

DER MAGNETISMUS DUENNER NICKEL- UND KOBALTFILME IN KONTAKT MIT NICHTMAGNETISCHEN METALLEN = MAGNETISM OF NICKEL AND COBALT THIN FILMS IN CONTACT WITH NON MAGNETIC METALS = LE MAGNETISME DES COUCHES MINCES DE NICKEL ET DE COBALT AU CONTACT DE METAUX NON MAGNETIQUESKRAMER I.1982; BERICHTE DER KERNFORSCHUNGSANLAGE JUELICH; ISSN 0366-0885; DEU; DA. 1982; NO 1818; 53 P.; ABS. ENG; BIBL. 31 REF.Serial Issue

The impact of zidovudine (AZT) therapy on the survivability of those with the progressive HIV infectionKRAMER, I.Mathematical and computer modelling. 1996, Vol 23, Num 3, pp 1-14, issn 0895-7177Article

Deriving the HIV incubation period distribution for AIDS using immunological markers and devising infection treatment strategiesKRAMER, I.Mathematical and computer modelling. 1994, Vol 19, Num 5, pp 65-91, issn 0895-7177Article

A dynamical model estimating the upper and lower bounds of the infectivity of the HTLV-III/LAV virus for the male bisexual and homosexual population in the absence of preventative measuresKRAMER, I.Computers & mathematics with applications (1987). 1987, Vol 14, Num 9-12, pp 817-828, issn 0898-1221Article

A unified approach to modeling the HIV infection in pediatric and adult AIDS risk groupsKRAMER, I.Mathematical and computer modelling. 1994, Vol 20, Num 9, pp 51-68, issn 0895-7177Article

Accurately simulating the growth in the size of the HIV infected population in any AIDS epidemic country: computing the USA HIV infection curveKRAMER, I.Mathematical and computer modelling. 1994, Vol 19, Num 2, pp 91-112, issn 0895-7177Article

Mathematically modelling the future AIDS incidence in MarylandKRAMER, I.Mathematical and computer modelling. 1992, Vol 16, Num 10, pp 25-44, issn 0895-7177Article

Understanding the time delay between HIV infection and aids from a model of HIV's impact on the T-Helper cell densityKRAMER, I.Mathematical and computer modelling. 1992, Vol 16, Num 12, pp 55-60, issn 0895-7177Article

Epidemiological evidence and immunological/mathematical model of acquired cytotoxic T lymphocyte immunity to HIV infection in AIDS risk populationsKRAMER, I.Mathematical and computer modelling. 1999, Vol 30, Num 5-6, pp 211-228, issn 0895-7177Article

Modeling the dynamical impact of HIV on the immune system : Viral clearance, infection, and AIDSKRAMER, I.Mathematical and computer modelling. 1999, Vol 29, Num 6, pp 95-112, issn 0895-7177Article

Is AIDS an invariably fatal disease? : a model analysis of AIDS survival curvesKRAMER, I.Mathematical and computer modelling. 1991, Vol 15, Num 9, pp 1-19, issn 0895-7177Article

Compatibility of amsacrine (Amsidyl®) concentrate for infusion with polypropylene syringesKRÄMER, I; MAAS, B.Pharmazie. 1999, Vol 54, Num 7, pp 538-541, issn 0031-7144Article

H₂-Antihistaminika. XXV: Synthese und H₂-antagonitische Wirkung monosubstituierter 1,2,4-Oxadiazol-3,5-diamine = Antihistaminiques H₂. XXV: Synthèse et activité antagoniste H₂ d'oxadiazole-1,2,4diamines-3,5 monosubstituées = H₂-antihistaminics. XXV: Synthesis and H₂-antagonistic activity of monosubstituted 1,2,4-oxadiazole-3,5-diaminesKRÄMER, I; SCHUNACK, W.Archiv der Pharmazie (Weinheim). 1985, Vol 318, Num 10, pp 888-895, issn 0365-6233Article

Wirkstofffreisetzung aus Matrixzubereitungen bei gleichzeitigem Wirkstoffabbau ― Mathematische Ermittlung der wahren Freisetzung = Libération des médicaments dégradables à partir de préparations matricielles ― évaluation mathématique des profils réels de libération = Release of degradable drugs from matrix preparations ― mathematical evaluation of true release profilesKRÄMER, I; MOLL, F.Acta pharmaceutica technologica. 1989, Vol 35, Num 4, pp 224-231, issn 0340-3157Article

Synthese und H₂-antagonistische Wirkung N,N'-substituierter 1,3,4-Oxadiazol-2,5-diamine. XXX: H₂-AntihistaminikaKRÄMER, I; SCHUNACK, W.Arzneimittel-Forschung. 1986, Vol 36, Num 11, pp 1564-1567, issn 0004-4172Article

Synthese und H₂-antagonistische Wirkung N,N'-substituierter 1,3,4-Oxadiazol-2,5-diamine. XXX: H₂-Antihistaminika = Synthèse et activité antihistaminique des N,N'-diamines-2,5 substituées oxadiazole-1,3,4 = Synthesis and H₂-antagonistic activity of N,N'-substituted 1,3,4-oxadiazole-2,5-diamines/30th communication=H₂-antihistaminicsKRÄMER, I; SCHUNACK, W.Arzneimittel-Forschung. 1986, Vol 36, Num 11, pp 1564-1567, issn 0004-4172Article

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancerKRÄMER, I; LIPP, H.-P.Journal of clinical pharmacy and therapeutics (Print). 2007, Vol 32, Num 1, pp 1-14, issn 0269-4727, 14 p.Article

H₂-Antihistaminika. XXXII: Synthese ung H₂-antagonistiche Wirkung von N-[3-(3-Piperidino-methyl-phenoxy)propyl]-1.3.4-oxadiazol-2-aminen = Antihistaminiques H₂. XXXII: Synthèse et action antagoniste H₂ de N-[(pipéridinométhyl-3 phénoxy)-3 propyl] oxadiazole-1,3,4ylamines-2 = H₂-Antihistaminiques. XXXII: Synthesis and H₂-antagonistic activity of N-[3-(3-(piperidinomethyl) phenoxy) propyl]-1,3,4-oxodiazol-2-aminesKRÄMER, I; SCHUNACK, W.Archiv der Pharmazie (Weinheim). 1986, Vol 319, Num 12, pp 1091-1098, issn 0365-6233Article

Physico-chemical stability of infusion solutions for epidural administration containing fentanyl and bupivacaine or lidocaineSATLER, A; JAGE, J; KRÄMER, I et al.Pharmazie. 1998, Vol 53, Num 6, pp 386-391, issn 0031-7144Article

The APEX digital fast fourier transform spectrometer : First science with APEXKLEIN, B; PHILIPP, S. D; KRÄMER, I et al.Astronomy and astrophysics (Berlin. Print). 2006, Vol 454, Num 2, issn 0004-6361, L29-L32Article

H₂-Antihistaminika. XXVIII: Synthese und H₂-antagonistische Wirkung 3-(3-piperidinomethylphenoxy)propyl-substituierter Kohlensäurederivate und Analoge = Antihistaminiques H₂. XXVIII: Synthèse et activité antagoniste H₂ de dérivés de l'acide carbonique et d'analogues substitués par le groupe (pipéridinométhyl-3 phénoxy)-3 propyl = H₂-Antihistaminics. XXVIII: Syntheses and H₂-antagonistic activity of derivatives of carbonic acid and analogues carrying a 3-[3-(piperidinomethyl) phenoxy] propyl substituentBUSCHAUER, A; KRÄMER, I; SCHUNACK, W et al.Archiv der Pharmazie (Weinheim). 1986, Vol 319, Num 5, pp 434-443, issn 0365-6233Article

Induction of resistance to bacterial pathogens in the pathosystem tomato/Clavibacter michiganensis subsp. michiganensis. II. Characterization of the resistance inductorGRIESBACH, E; EISBEIN, K; KRÄMER, I et al.Zeitschrift für Pflanzenkrankheiten und Pflanzenschutz (1970). 2000, Vol 107, Num 5, pp 464-483, issn 0340-8159Article

H₂-Antihistaminika. XXXIII: Synthese und H₂-antagonistische Aktivität heteroaromatischer (Thio)Carboxamide und Triazol(thi)on-Derivate des Piperidinomethylphenoxypropylamins = Antihistaminiques H2. XXXIII: Synthèse et activité antagoniste H2 de dérivés hétéroaromatiques(thio)carboxamides et triazole(thi)ones de pipéridinométhylphenoxypropylamine = H2-Antihistaminics. XXXIII: Synthesis and H2-antagonist activity of heteroaromatic(thio)carboxamides and triazole(thi)ones derivatives of piperidinomethylphenoxypropylamineWEGNER, K; KRÄMER, I; SCHUNACK, W et al.Archiv der Pharmazie (Weinheim). 1987, Vol 320, Num 2, pp 108-114, issn 0365-6233Article